These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 33241993)
1. Inflammatory Activity and Treatment Response in Pediatric Compared to Adult Multiple Sclerosis: A Pilot, Retrospective and Observational Study of the First Year After Diagnosis. De Carvalho S; Pinto J; Correia I; Faustino R; Vasconcelos M; Sousa L; Palavra F Acta Med Port; 2021 Jan; 34(1):28-34. PubMed ID: 33241993 [TBL] [Abstract][Full Text] [Related]
2. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427 [TBL] [Abstract][Full Text] [Related]
3. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054 [TBL] [Abstract][Full Text] [Related]
4. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R; CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772 [TBL] [Abstract][Full Text] [Related]
5. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055 [TBL] [Abstract][Full Text] [Related]
6. Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report. Capobianco M; Bertolotto A; Malucchi S Neurol Sci; 2021 May; 42(Suppl 1):25-28. PubMed ID: 33712907 [TBL] [Abstract][Full Text] [Related]
7. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon. Zafar A; AlShamrani FJG Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260 [TBL] [Abstract][Full Text] [Related]
8. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172 [TBL] [Abstract][Full Text] [Related]
9. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843 [TBL] [Abstract][Full Text] [Related]
10. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T; Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096 [TBL] [Abstract][Full Text] [Related]
11. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931 [TBL] [Abstract][Full Text] [Related]
13. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. Sinnecker T; Clarke MA; Meier D; Enzinger C; Calabrese M; De Stefano N; Pitiot A; Giorgio A; Schoonheim MM; Paul F; Pawlak MA; Schmidt R; Kappos L; Montalban X; Rovira À; Evangelou N; Wuerfel J; JAMA Neurol; 2019 Dec; 76(12):1446-1456. PubMed ID: 31424490 [TBL] [Abstract][Full Text] [Related]